Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (NASDAQ: PGNY) has launched its new Parent and Child Well-being offering, expanding its family building solutions portfolio. The program aims to support working parents and caregivers with comprehensive services addressing return-to-work challenges and emotional health support.
The offering comes as statistics show nearly 40% of the U.S. workforce are parents with children under 18, with 48% reporting overwhelming daily stress. The program features:
- Personalized support from licensed clinical social workers
- Benefit navigation assistance for leave planning and paperwork
- Digital tools including educational content and webinars
- Return-to-work transition support
The service is designed to enhance job satisfaction and retention while providing continuous support from preconception through early childhood development. The program is available to employers and health plans.
Progyny (Nasdaq: PGNY), a leader in fertility, family building, and women's health benefits solutions, has announced its participation in three major investor conferences in March 2025.
The company's schedule includes:
- A fireside chat at the Leerink Partners Global Healthcare Conference in Miami on March 10, 2025, at 11:20 a.m. ET
- Meetings at the Barclays 27th Annual Global Healthcare Conference in Miami on March 11, 2025
- A virtual fireside chat with CEO Pete Anevski at the KeyBanc Capital Markets Healthcare Forum on March 19, 2025, at 2:15 p.m. ET
Live audiocasts and replays of the fireside chats will be accessible through Progyny's investor relations website at investors.progyny.com.
Progyny (NASDAQ: PGNY) reported Q4 2024 financial results with revenue of $298.4 million, up 10.6% year-over-year. The fertility benefits company generated quarterly operating cash flow of $52.2 million.
Key Q4 metrics include: fertility benefit services revenue of $187.5M (+9%), pharmacy benefit services revenue of $111.0M (+13%), gross profit of $63.4M (+11%), and net income of $10.5M. The company ended 2024 with 473 clients, up from 392 in 2023.
For full-year 2024, Progyny achieved revenue of $1.17B (+7.2%), net income of $54.3M, and Adjusted EBITDA of $198.8M. The company issued 2025 guidance projecting revenue between $1.175B-$1.225B (+1-5%) and expects to serve over 530 clients representing approximately 6.7 million covered lives.
Progyny (Nasdaq: PGNY), a fertility, family building, and women's health benefits solution provider, has scheduled its Q4 and Full Year 2024 financial results announcement for February 27, 2025, after market close. The company will host a conference call at 4:45 p.m. ET, accessible to U.S. participants at 1.866.825.7331 and international participants at 1.973.413.6106 (passcode: 265484).
An audio replay will be available until March 6, 2025, and can be accessed at 1.800.332.6854 (U.S.) or 1.973.528.0005 (international). A live webcast and recording will be available on the company's investor relations website.
Progyny (NASDAQ: PGNY) has announced the acquisition of BenefitBump, a parental leave benefits navigation program, expanding its fertility and family building services portfolio. The acquisition aims to address the needs of 90% of parents seeking greater support in managing work-home responsibilities.
The enhanced service suite will include a clinical social worker-led parental wellness program, comprehensive parental leave and benefits navigation, care and resource navigation for child behavior concerns and neurodiverse care, and clinician-facilitated peer support groups. This integration extends Progyny's existing services across preconception, fertility, pregnancy, postpartum, and menopause care.
The acquisition is designed to reduce member stress, improve recruitment, return-to-work and retention rates, and foster proactive child and family health by eliminating fragmentation in family support services.
Progyny (Nasdaq: PGNY) has appointed Debra Morris, a 30-year healthcare industry veteran, to its board of directors effective January 16, 2025. Morris, who currently serves as President of AccessHope, brings extensive experience in healthcare operations and financial management. She previously held the position of EVP and CFO at Apria Healthcare.
Morris will serve on the Compensation Committee and brings personal experience with infertility along with professional expertise in scaling organizations, healthcare systems, payment models, and operational efficiency. CEO Pete Anevski highlighted Morris's ability to navigate periods of rapid growth as particularly valuable for Progyny's continued expansion of family building and women's healthcare solutions.
Progyny (Nasdaq: PGNY), a leader in fertility, family building, and women's health benefits, announced its participation in the 43rd Annual JP Morgan Healthcare Conference. The company plans to discuss updated financial expectations for the fourth quarter and full year ending December 31, 2024. In the November earnings call, Progyny had anticipated flat to declining member activity for Q4 compared to Q3 2024, due to earlier variability.
However, CEO Pete Anevski reported improved member activity and treatment volume, leading Progyny to expect Q4 results for revenue, net income, and Adjusted EBITDA to be slightly above previous guidance ranges. Anevski will present at the conference on January 14, 2025, at 7:30 a.m. PT / 10:30 a.m. ET, followed by a breakout session with key executives. A live audiocast and replay will be available on Progyny's investor relations website.
Cigna Healthcare announced a new collaboration with Progyny, Inc (Nasdaq: PGNY) to offer expanded fertility and family-building services for more employers. This comprehensive benefit aims to provide coverage from pre-conception to postpartum care, including surrogacy and adoption. The initiative addresses the affordability challenges employers face and acknowledges the growing demand for such services, with 1 in 6 people affected by infertility globally.
The offering is designed to help employers attract and retain top talent, with 61% of millennials valuing these benefits for company loyalty and 70% willing to change jobs for better family-planning benefits. Progyny's Smart Cycle® design allows employers to simplify coverage based on fertility cycles rather than financial thresholds, offering services such as:
- Access to over 650 premier fertility clinics in the U.S.
- 1:1 personalized support from Patient Care Advocates.
- Pre-conception coaching and clinical programming.
- Prescription fertility medication coverage.
- Customized cycle-based coverage for reproductive technologies.
- Egg and sperm freezing and storage.
- Doula services for labor and delivery.
- Holistic well-being and mental health support.
- Guided support and reimbursement for surrogacy and adoption services.
This new benefit will be available to most of Cigna Healthcare's self-funded employer clients in early fall 2025.
Progyny (Nasdaq: PGNY), a provider of fertility, family building, and women's health benefits solutions, has announced its participation in the Jefferies London Healthcare Conference. CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat on Tuesday, November 19, 2024, at 8:00 a.m. GMT (3:00 a.m. EST).
Interested parties can access both the live audiocast and replay through the Events and Presentations section on Progyny's investor website at http://investors.progyny.com.
Progyny reported Q3 2024 revenue of $286.6 million, up 2.0% year-over-year, with net income of $10.4 million. The company secured over 80 new clients and 1.1 million new covered lives during the sales season. However, lower-than-expected revenue and profitability occurred as members took longer to progress through treatments. Gross margin decreased to 20.7% from 22.3% in Q3 2023. The company was selected by two health plans as their preferred partner and saw 1.5 million lives adopt their newest maternity and menopause programs for 2025. For full-year 2024, revenue guidance was revised to $1.135-1.150 billion.